GSK first quarter
This article was originally published in The Tan Sheet
Executive Summary
Pharma company's smoking cessation unit recovered from a disappointing fourth quarter 2003 and advanced 17% in the first quarter 2004 to drive Consumer Healthcare revenues up 6% to $1.3 bil. Boosted by NRT products, OTC medicine sales were ahead 2% to $627.3 mil. Analgesic sales rose 12%, helping to offset an 18% drop in dermatological product sales. Oral care sales increased 6% to $462 mil. based on strong performances of Aquafresh and Sensodyne. Nutritional healthcare grew 13% due to strong international and European growth. ...
You may also be interested in...
GSK Hopes To Energize Tagamet HB By Targeting New Male Audience
GlaxoSmithKline Consumer Healthcare is attempting to reinvigorate its OTC Tagamet heartburn remedy brand with a new marketing and advertising campaign targeting young males
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.